Lovisa Afzelius

Cambridge, Massachusetts, United States
Lovisa Afzelius is an origination partner at Flagship Pioneering and co-founder and founding
CEO of Alltrna, Apriori Bio and Flagship Labs 72 and 89. A computational scientist by
training, she brings to Flagship two decades of leadership experience in emerging biotechs
and large pharma companies, and a passion for data-driven drug discovery.

Before joining the Flagship ecosystem, Lovisa built and led Pfizer’s systems immunology
function and served as executive director of clinical programs. In 2017, she co-founded
Elsa.science, a digital health company for which she serves on the board.

Lovisa began her career at AstraZeneca and has received numerous accolades for her work,
including being named one of the 100 “most influential persons under 40 in Sweden” by the
business magazine, Affärsvärlden. She holds a Ph.D. in computational chemistry from
Uppsala University, a Master of Science in integrative pharmacology from Gothenburg
University as well as an M.B.A. from MIT.
Speaking In
11:00 AM - 12:00 PM
Tuesday, June 6
The advent of mRNA vaccines, accelerated by the global SARS-Cov-2 pandemic, marked the beginning of…